Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 17, 2007

Xenomics and Ipsogen Partner to Advance Diagnostic Tool for Leukemia

  • Xenomics granted Ipsogen co-exclusive rights to develop, manufacture, and market research and diagnostic products for the stratification and monitoring of patients with acute myeloid leukemia (AML).

    AML is a clinically and molecularly heterogeneous disease. Subgrouping by cytogenetic karyotyping indicates patient prognosis. However, in almost half of AML cases the karyotype appears normal, according to the firms. A recent discovery showed that about 60% of adult AML with normal karyotype have a mutation in the nucleophosmin (NPM1) gene, they add.

    Xenomics reports that it has developed a test that detects all known 45 mutations of NPM1 in one reaction. In addition, the company says that it designed a sensitive NPM1 monitoring test that can detect the presence of residual disease following chemotherapy.

    It is hoped that the combination of NPM1 diagnostic and monitoring assays can provide effective means of assessing and stratifying patients during clinical trials.

    “The NPM1 products will integrate Ipsogen quantitative and standardized technology, FusionQuant® and ProfileQuant®, to warrant the highest level of precision and quality for clinical laboratories and patients,” states Vincent Fert, president and CEO of Ipsogen.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »